Phase II Study of GW786034 in Patients With Relapsed or Refractory Soft Tissue Sarcoma.

Trial Profile

Phase II Study of GW786034 in Patients With Relapsed or Refractory Soft Tissue Sarcoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Soft tissue sarcoma
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 12 Sep 2017 Results (n=333) of EORTC62043 and EORTC62072 trials assessing evolution in neutrophil to lymphocyte ratio in patients with advanced soft tissue sarcoma, presented at the 42nd European Society for Medical Oncology Congress.
    • 12 Sep 2017 Results of a pooled analysis from EORTC 62012,EORTC62043 EORTC 62072 and EORTC62091 trials presented at the 42nd European Society for Medical Oncology Congress
    • 11 Oct 2016 Results of a retrospective analysis from EORTC6204, EORTC62072 studies and additional clinical data from real life setting investigating the activity of pazopanib in vascular sarcomas, presented at the 41st European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top